Roche and Gilead join forces

Roche and Gilead join forces

Two major pharmaceutical companies fight together against the virus.

Yesterday, pharmaceutical giant Roche stated that it joined forces with Gilead to combine a drug from each of them and test the mix to see if the result is a viable treatment against the severe cases of Covid-19.

From Roche's point of view, the first two phases will include a clinical status, a mortality rate testing, mechanical ventilation, and intensive care. After the treatment is over, the patient is to stay under observation for 60 days.

The partnership includes a Phase III clinical trial where Roche’s Tocilizumab and Gilead’s Remdesivir will undergo tests for efficacy and safety. The test will be conducted on 450 patients from the US, Canada, and Europe. The mixture will be up for trial against a placebo also.

The two companies came together after the two drugs had promising results separately. Roche believes that if combined, the result will be more effective. “We believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease,” Roche’s CMO, Levi Garraway, stated.

Each of the drugs is viable for treating other diseases, such as arthritis and Ebola, but they showed results in treating extreme inflammation and respiratory deficiency. Moreover, Remdesivir is approved in the US and Japan for emergency use only, at the moment. Analysts say European authorities are thinking about doing the same.

Gilead stock gained 1.52% during yesterday’s trading session; Roche’s added 2.4% in pre-market. Since the beginning of the year, Gilead gained 15.2% in market value, while Roche went up 8.2%. USA500 dropped 6% over the same time frame.

Stay up to date with CAPEX.com! Register now!

Sources: thesteet.com, reuters.com, pharmatimes.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.